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Members of the WNK (with-no-lysine [K]) subfamily of protein kinases regulate various ion channels
involved in sodium, potassium, and chloride homeostasis by either inducing their phosphorylation or regu-
lating the number of channel proteins expressed at the cell surface. Here, we describe findings demonstrating
that the cell surface expression of the cystic fibrosis transmembrane conductance regulator (CFTR) is also
regulated by WNK4 in mammalian cells. This effect of WNK4 is independent of the presence of kinase and
involves interaction with and inhibition of spleen tyrosine kinase (Syk), which phosphorylates Tyr512 in the
first nucleotide-binding domain 1 (NBD1) of CFTR. Transfection of catalytically active Syk into CFTR-
expressing baby hamster kidney cells reduces the cell surface expression of CFTR, whereas that of WNK4
promotes it. This is shown by biotinylation of cell surface proteins, immunofluorescence microscopy, and
functional efflux assays. Mutation of Tyr512 to either glutamic acid or phenylalanine is sufficient to alter CFTR
surface levels. In human airway epithelial cells, downregulation of endogenous Syk and WNK4 confirms their
roles as physiologic regulators of CFTR surface expression. Together, our results show that Tyr512 phosphor-
ylation is a novel signal regulating the prevalence of CFTR at the cell surface and that WNK4 and Syk perform
an antagonistic role in this process.
Ion transport across the plasma membrane is regulated by
posttranslational mechanisms that rapidly modify the amount
of ion channel proteins present at the plasma membrane and/or
their transport activity, processes requiring tight regulation by
signaling mechanisms.
One novel signaling pathway in the kidney that involves
members of the WNK (with-no-lysine [K]) protein kinase fam-
ily of serine/threonine protein kinases was recently identified
(43). It was found that mutations in the WNK1 and WNK4
genes result in increased renal sodium (Na) and chloride
(Cl) reabsorption and impaired potassium (K) secretion,
manifesting as the inherited syndrome of hypertension and
hyperkalemia, also known as pseudohypoaldosteronism type II
(PHA2) or Gordon’s syndrome (45). Affected patients carry
missense mutations in WNK4 that, when expressed in cell mod-
els, have been shown to lead to the deregulation of the renal
Na/Cl cotransporter (NCC) and renal outer medullary po-
tassium channel 1 (ROMK1) (13, 21, 32, 46). Results of anal-
ysis of transgenic mouse models of the disease suggest that
changes in both the surface expression and the activity of NCC
are the main pathological mechanisms underlying PHA2 (23,
30, 50).
The ion transport activity of the NCC, as well as of the
related Na/K/Cl cotransporter 1 (NKCC1) and NKCC2
channels, is regulated by phosphorylation on N-terminal
threonine residues by one of two STE20-family protein ki-
nases, Ste20-related proline and alanine-rich kinase (SPAK)
or oxidative stress-responsive kinase 1 (OSR1) (20, 31, 33).
Both kinases require activation by WNK4, which phosphor-
ylates residue Thr233 in SPAK or Thr185 in OSR1 (12, 28, 44).
WNK4 can further regulate the surface amount of other
renal or extrarenal ion channels in a kinase-independent man-
ner when expressed in Xenopus oocytes or mammalian cells.
These include NCC (5, 14, 37, 46, 47, 49, 52), the Cl/HCO3
exchangers SLC26A6 (19) and SLC16A9 (8), ROMK1 (22, 29,
35), the epithelial Na channel (ENaC) (16, 34), transient
receptor potential vanilloid calcium channel 4 (TRPV4) (10)
and TRPV5 (7, 18), and the cystic fibrosis (CF) transmem-
brane conductance regulator (CFTR) Cl channel (48), mu-
tation of which is the cause of CF.
In the case of ROMK and TRPV5, mutant WNK4 was shown
to interact with the scaffold protein Intersectin and promote
channel endocytosis (7, 15, 22), but whether other mechanisms
exist through which WNK4 regulates ion channel surface ex-
pression remains unknown. The elucidation of such mecha-
nisms may help to identify drug targets to correct the insuffi-
cient channel activity that underlies several diseases (6, 17).
For example, in CF patients, the lack of CFTR activity leads to
dehydrated, thick mucus in the lungs and subsequent chronic
bacterial infections; however, disease symptoms would be sig-
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nificantly reduced if only about 10% of CFTR activity could be
restored in patients (2).
Here we identified a novel signaling mechanism linking the
cell surface expression of CFTR to protein kinase WNK4 and
the spleen tyrosine kinase (Syk). Syk is a cytoplasmic non-
receptor tyrosine kinase best known for its proinflammatory
role in immunoreceptor signaling in leukocytes (27). We
show in this work that Syk can phosphorylate CFTR and
decrease surface CFTR expression and that the interaction of
WNK4 with Syk prevents CFTR phosphorylation and pro-
motes an increase in CFTR-mediated ion transport.
MATERIALS AND METHODS
Cell culture and transfections. HEK293 (human embryonic kidney) cells were
maintained in Dulbecco’s minimal essential medium (DMEM) supplemented
with 10 U of penicillin/ml, 10 g of streptomycin/ml, and 10% fetal calf serum
(Invitrogen S.A., Barcelona, Spain) and were regularly checked for the absence
of mycoplasm infection. Baby hamster kidney (BHK-21) cells stably expressing
human wild-type (wt) CFTR (BHK-21-CFTR) (26, 38) were maintained in
DMEM-F12 medium supplemented with L-glutamine, 15 mM HEPES, 10 U of
penicillin/ml, 10 g of streptomycin/ml, 0.2% methotrexate, and 5% fetal calf
serum (Invitrogen). The CF patient-derived human bronchial epithelial cell line
CFBE41o-, stably expressing wild-type CFTR (3) (generous gift from J. P.
Clancy, University of Alabama at Birmingham), was grown at 37°C under con-
ditions of 5% CO2, in minimal essential medium (MEM) supplemented with
L-glutamine, 10% FBS, and penicillin-streptomycin (all from Invitrogen, Spain).
The cells were routinely grown on plastic flasks coated with fibronectin-vitrogen-
bovine serum albumin (fibronectin-vitrogen-BSA) as previously described (3).
All cell lines were regularly checked for absence of mycoplasm infection.
For ectopic expression of plasmid cDNAs, HEK293 cells were transfected at
80 to 90% confluence using Metafectene (Biontex, Martinsried/Planegg, Ger-
many) according to the manufacturer’s instructions. BHK-21 cells were trans-
fected at 80 to 90% confluence using Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s instructions. Transfection efficiencies were found to be
around 90%, as determined microscopically using a green fluorescent protein
(GFP) expression vector. The amount of transfected plasmid DNA was kept
constant at 4 g per 60-mm-diameter dish or 2 g per 35-mm-diameter dish;
constructs were supplemented with empty vector if required. For immunofluo-
rescence studies, constructs were diluted 1:4 with empty pcDNA3 vector to
reduce transfection efficiency and allow imaging of transfected and nontrans-
fected cells side by side. All transfected cells were analyzed after 20 h for
biochemical assays or after 16 h for immunofluorescence experiments. For down-
regulation of endogenous proteins, 300 pmol of the corresponding specific small
interfering RNAs (siRNAs), namely, sc-29501 (from Santa Cruz Biotechnolo-
gies) against Syk and NM_032387si5 (5ACA CUA CAG ACA CUA CAG A)
(from Eurofins MWG Operon, Ebersberg, Germany) against WNK4, was trans-
fected into CFBE41o- cells by the use of Lipofectamine 2000 (Invitrogen). A
luciferase GL2 siRNA (Eurofins MWG Operon) was used as a control, and cells
were analyzed 48 h after transfection. All results were confirmed in at least three
independent transfection experiments.
Transcript expression analysis. Total RNA was extracted from CFBE cells by
the use of an RNeasy kit (Qiagen, Hilden, Germany), and 1 g of the extracted
content was used for reverse transcription (RT) using random primers (Invit-
rogen) and Ready-to-Go You-Prime beads (GE Healthcare, Buckinghamshire,
United Kingdom). The primers for specific amplification of WNK4 were
WNK4_ex12F (5CAG ACG GAT TCG GGA GAT TA) and WNK4_ex14R
(5TGG GTT TCC AGG AGA CAA AG), for Syk were Syk SI-F (5AGC TGG
ACA ACC CGT ACA TC) and Syk SI-R (5TGT GCA CAA AAT TGC TCT
CC), and for RNA polymerase II (POLR2) were pol II-F (5-GAG CGG GAA
TTT GAG CGG ATG C) and pol II-R (5-GAA GGC GTG GGT TGA TGT
GGA AGA). Amplification reactions were performed using AmpliTaq polymer-
ase (Perkin Elmer, Wellesley, MA) and 35 cycles of 94°C for 20 s, 58°C for 20 s,
and 72°C for 20 s, with an initial denaturation of 5 min at 94°C and a final
extension of 10 min at 72°C for WNK4, 28 cycles of 94°C for 30 s, 58°C for 30 s,
and 72°C for 30 s for Syk, or 28 cycles of 94°C for 30 s, 64°C for 30 s, and 72°C
for 30 s for POLR2. These amplification conditions were semiquantitative and
experimentally determined to correspond to the linear amplification phases.
Products were separated on 2% agarose gels, and band intensity was quantified
using Image J software followed by POLR2 normalization. No amplification was
obtained when RNA was mock reverse transcribed without addition of reverse
transcriptase.
Expression constructs. Partial cDNA clones encoding human WNK4 and its
kinase-dead mutant K186A (both kindly provided by X. Jeunemaître, Paris,
France) were completed by substituting a PCR-amplified 2-kb fragment to gen-
erate a complete WNK4 sequence identical to that corresponding to GenBank
accession no. NM_032387. The WNK4 cDNAs were then subcloned into either
pEGFP (BD Biosciences Europe, Erembodegem, Belgium) or pcDNA3-Myc
(Invitrogen) expression vector. The yellow fluorescent protein-Syk (YFP-Syk)
vector (whose coding sequence corresponds to that of GenBank NM_001135052)
was purchased from RZPD-ImaGenes (Berlin, Germany), and its kinase-dead
mutant, YFP-Syk-K402R, was generated by mutating codon 402 from AAA to
AGA by the use of a QuikChange mutagenesis kit (Stratagene, La Jolla, CA).
pET-Sumo-NBD1 (the first nucleotide binding domain [NBD]of CFTR; kindly
provided by Philip J. Thomas, Dallas, TX) was mutated at CFTR codon 512 from
TAT to TTT to obtain pET-Sumo-NBD1-Y512F. For subcloning of Myc-tagged
NBD1 and NBD1-Y512F, their cDNAs, which correspond to CFTR codons 388
to 677, were amplified from pET-Sumo-NBD1 by the use of primers NBD1-F (5
ACG ACT ACA GAA GTA GTG ATG) and NBD1-R (5 TTA GAC AGG
AGC ATC TCC TTC), cloned into pCR2.1 Topo-TA vector (Invitrogen), and
transferred into a pcDNA3-Myc expression vector. CFTR-Y512F and CFTR-
Y512E mutants were generated by changing codon 512 of human pNUT-CFTR
(26) from TAT to TTT and GAG, respectively. Protein kinase OSR1 (oxidative
stress-responsive kinase 1) was amplified from cDNA clone IRAUp969A0428D
(RZPD-ImaGenes, Berlin, Germany) by PCR with primers Bam-OSR1-F (5
GGA TCC ATG TCC GAG GAC TCG AG) and Hind-OSR1-R (5 TTC GAA
TTA GCT GAT GCT GAG CTG), cloned into pCR2.1 Topo-TA vector, and
then subcloned into the BamHI and HindIII sites of T7/His-tagged pET28 vector
(Novagen). Subsequently, codon 164 of the cDNA was mutated from GAC to
GCC to generate the kinase-dead OSR1-D164A mutant, which was used as a
substrate for in vitro protein kinase assays. Myc-tagged hnRNP A1 (a gift from H.
Ko¨nig, Karlsruhe, Germany) was as described previously (25). All constructs
were verified by automated DNA sequencing.
Coimmunoprecipitation and Western blot procedures. For coimmunoprecipi-
tation experiments, cells were grown in 60-mm-diameter dishes (transfected
cells) and lysed on ice in 250 l of nondenaturing lysis buffer (50 mM Tris-HCl
[pH 7.5], 1% NP-40, 100 mM NaCl, 10% glycerol, 10 mM MgCl2) supplemented
with a protease inhibitor cocktail composed of 1 mM phenylmethylsulfonyl
fluoride (PMSF), 1 mM 1,10-phenanthroline, 1 mM EGTA, 10 M E64, and 10
g/ml of each aprotinin, leupeptin, and pepstatin A (all from Sigma-Aldrich
Quimica, Madrid, Spain). The cell lysates were incubated for 2 h at 4°C with the
specified antibodies, namely, anti-GFP ab1218 (Abcam, Cambridge, United
Kingdom) (2.5 g/ml) and anti-Myc clone 9E10 (M5546; Sigma-Aldrich), further
incubated for 1 h with protein G-agarose beads (Roche Applied Science, Indi-
anapolis, IN), and finally washed three times in cold lysis buffer containing 200
mM NaCl. Proteins were solubilized from the beads in 2 sodium dodecyl
sulfate (SDS) sample buffer and separated in a 10% SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) Protean III minigel (Bio-Rad, Hercules, CA). All
gels intended for assessment of CFTR expression contained 1% glycerol and
were run at 4°C. For detection of specific proteins, the polyacrylamide gel was
transferred onto a polyvinylidene difluoride (PVDF) membrane (Bio-Rad) by
the use of a Mini Trans-Blot cell (Bio-Rad) (100 V for 1 h) followed by Coo-
massie staining to check for equal transfer results. Western blot membranes were
blocked in Tris-buffered saline (TBS)–0.1% Triton X-100–5% milk powder,
probed using the indicated antibodies, and then incubated with a secondary
peroxidase-conjugated antibody (Bio-Rad) followed by chemiluminescence de-
tection. Primary antibodies used for Western blot analyses were rabbit anti-Myc
A14 (sc-789) from Santa Cruz Biotechnologies (Santa Cruz, CA), rabbit anti-
GFP ab290 from Abcam (Cambridge, United Kingdom), mouse anti-T7-tag from
Merck4Biosciences (Nottingham, United Kingdom), mouse anti-human trans-
ferrin receptor (TfR) (clone H68.4; Invitrogen Corporation, CA), mouse anti-
CFTR clone 596 (obtained through the University of North Carolina at Chapel
Hill [UNC] CFTR antibody distribution program sponsored by Cystic Fibrosis
Foundation Therapeutics, Inc. [CFFT]) to detect full-length CFTR in cell ex-
tracts, mouse anti-CFTR clone L12B4 (mAb3484) from Chemicon International
(Billerica, MA) to detect recombinant NBD1 (rNBD1), and affinity-purified
rabbit anti-CFTR (Lis1) (9) to detect CFTR in immunoprecipitates obtained
with mouse anti-GFP.
For protein-protein interaction screening, a signal transduction antibody array
from Hypromatrix (Worcester, MA) containing antibodies against 400 cellular
proteins involved in signal transduction was used. The array membranes were
incubated for 2 h at room temperature with cell lysates prepared in nondena-
turing lysis buffer from four 60-mm-diameter dishes of HEK293 cells transfected
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with either Myc-WNK4 or empty vector and then washed like Western blots
before being subjected to staining of the complexes containing Myc-WNK4 with
an anti-Myc peroxidase conjugate (from Hypromatrix).
Biotinylation of cell surface proteins. Cells were transfected as described
above, washed twice with warm culture medium to remove dead cells, and placed
on ice in a cold room. Cells were washed three times with ice-cold phosphate-
buffered saline–CM (PBS-CM) (PBS [pH 8.0] containing 0.1 mM CaCl2 and 1
mM MgCl2) and left for 5 min in cold PBS-CM to ensure arrest of endocytic
traffic. Cells were then incubated for 30 min with EZlink sulfo-NHS-SS-biotin
(catalog no. 21331; Pierce Biotechnology, Rockford, IL) (0.5 mg/ml) in PBS-CM
before being rinsed twice and left for 15 min on ice with ice-cold Tris-glycine (100
mM Tris-HCl [pH 8.0], 150 mM NaCl, 0.1 mM CaCl2, 1 mM MgCl2, 10 mM
glycine, 1% BSA) to quench the biotinylation reaction. Cells were again washed
3 times with cold PBS-CM and lysed in 250 l of pull-down buffer (50 mM
Tris-HCl [pH 7.5], 100 mM NaCl, 10% glycerol, 1% NP-40) in the presence of
the aforementioned protease inhibitor cocktail. The cell lysates were harvested
by scraping and cleared by centrifugation at 16,000  g at 4°C for 5 min. An
aliquot of 40 l representing the total CFTR level was removed and added to 2
CFTR sample buffer (62.5 mM Tris-HCl [pH 6.8], 3% SDS, 10% glycerol, 0.02%
bromophenol blue, 160 mM dithiothreitol [DTT]), while 200 l of lysate was
added to 25 l of streptavidin-agarose beads (Sigma-Aldrich) previously incu-
bated for 1 h in 1 ml of cold pulldown buffer containing 2% nonfat milk powder
and washed 3 times in pulldown buffer. For purification of biotinylated proteins,
lysates and beads were incubated under conditions of rotation for 1 h at 4°C, and
the beads were collected by centrifugation (1 min at 3,000  g) and washed 3
times in cold wash buffer (100 mM Tris-HCl [pH 7.5], 300 mM NaCl, 1% Triton
X-100). Captured proteins were recovered from the beads in 25 l of 2 CFTR
sample buffer without boiling. The biotinylated protein fraction and 1/20 of the
corresponding whole-cell lysate were analyzed alongside by SDS-PAGE followed
by Western blot transfer.
Production of recombinant OSR1 or Sumo-NBD1 and in vitro protein kinase
assays. For the production of recombinant human OSR1, a reported WNK4
substrate (44), or of recombinant human NBD1 domain, pET-OSR1-D164A,
pET-Sumo-NBD1, and pET-Sumo-NBD1-Y512F were expressed in the Esche-
richia coli BL21 strain under conditions of isopropylthiogalactosidase (IPTG)
(0.1 mM) induction and the bacterial pellets were harvested by centrifugation at
1,400 g for 20 min and frozen. For protein extraction, pellets were resuspended
in either conventional lysis buffer (50 mM Tris-HCl [pH 7.5], 50 mM NaCl, 5 mM
MgCl2, 1 mM DTT) for OSR1 or CFTR lysis buffer (50 mM Tris-HCl [pH 7.5],
100 mM L-arginine, 50 mM NaCl, 5 mM MgCl2, 12.5% glycerol, 0.25% NP-40,
0.1% SDS, 1 mM DTT, 2 mM ATP) in the presence of the protease inhibitor
cocktail described above and then sonicated (Sonics Vibra Cell sonicator, set at
40% amplitude) on ice for 10 cycles of 30 s with 10-s intervals. Following
centrifugation of the extract at 16,000  g, the supernatant was incubated with
nickel-nitrilotriacetic acid (Ni-NTA)–agarose beads (Qiagen, Hilden, Germany)
for 1 h at 4°C. Beads were washed twice with cold lysis buffer containing 20 mM
imidazole and protease inhibitors. Recombinant OSR1 was eluted and stored in
cold lysis buffer containing 250 mM imidazole, whereas recombinant Sumo-
NBD1 proteins were dialyzed using imidazole-free lysis buffer and then concen-
trated. Proteins were quantified and stored in aliquots at 80°C.
For in vitro protein kinase assays, cells were lysed under stringent conditions in
250 l of radioimmunoprecipitation (RIPA) buffer (50 mM Tris-HCl [pH 7.5],
1% NP-40, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate) supplemented
with protease inhibitors (see above). To reduce extract viscosity, benzonase
(Sigma-Aldrich) (500 U/ml) and 5 mM MgCl2 were added. Following immuno-
precipitation of WNK4 or Syk as described above, the resulting beads were
washed three times in cold RIPA buffer followed by three washes with nonde-
naturing lysis buffer and then resuspended in 20 l of kinase reaction buffer (30
mM Tris HCl [pH 7.5], 10% glycerol, 1 mM DTT, 1 mM Na3VO4, 10 mM MgCl2,
2 mM MnCl2, 150 M ATP), mixed with the corresponding substrate (1,000 ng
of recombinant kinase-dead OSR1 or recombinant NBD1 or beads containing
immunoprecipitated Myc-tagged NBD1 or full-length CFTR protein), and incu-
bated in the presence of 5 Ci of [-32P]ATP at 30°C for 30 min. When immu-
noprecipitated endogenous CFTR protein was used as the substrate, the in vitro
phosphorylation reaction was preceded by incubation with unlabeled ATP for 30
min at 30°C to reduce background phosphorylation. In addition, the reaction was
performed in the presence of inhibitors of protein serine/threonine kinases
known to phosphorylate CFTR in vitro (1), namely, 2 M bisindolylmaleimide II
(Sigma-Aldrich) to inhibit protein kinases C and A and 50 M quinalizarin
(1,2,5,8-tetrahydroxyanthraquinone) to inhibit casein kinase II (kind gift from L.
Pinna, Padua, Italy). Finally, 2 SDS sample buffer was added and samples were
boiled. For full-length CFTR, 2 CFTR sample buffer was added without boil-
ing. Samples were then separated by SDS-PAGE followed by Western blot
analysis. PVDF membranes were dried and first exposed to X-ray films for 10 to
72 h and subsequently rehydrated for immunodetection with the indicated anti-
bodies in order to document protein quantities.
Immunofluorescence microscopy. BHK-21 cells were grown on coverslips,
transfected as indicated, fixed after 16 h with 4% formaldehyde (catalog no.
104003; Merck Chemicals, Darmstadt Germany)–PBS, and permeabilized with
0.2% Triton X-100–PBS. Cells were then immunolabeled for 1 h with mouse
anti-CFTR (clone 570; obtained through the UNC CFTR antibody distribution
program sponsored by CFFT), washed 3 times for 5 min each time in PBS–0.01%
Tween 20 (PBS-T), incubated with a secondary Alexa 568-conjugated antibody
(Molecular Probes; Invitrogen), washed, stained briefly in DAPI (4,6di-
amidino-2-phenylindole) solution (Sigma) (1:1,000 in PBS-T), washed again, and
postfixed for 15 min in 4% (vol/vol) formaldehyde. Coverslips were mounted on
microscope slides with Vectashield (Vector Laboratories, Burlingame, CA), and
images were recorded on a Leica TCS-SPE confocal microscope and processed
with Adobe Photoshop software.
Iodide efflux assay. A CFTR-mediated iodide efflux assay was adapted from
previously described methods (24, 39, 51). BHK-21 cells were grown in 6-well
dishes, transfected in duplicate experiments as indicated, and, 20 h later, washed
twice and incubated for 30 min at 37°C in prewarmed iodide loading buffer (ILB)
[136 mM NaI, 3 mM KNO3, 2 mM Ca(NO3)2, 0.5 mM MgSO4, 10 mM glucose,
20 mM HEPES (pH 7.5)]. Cells were then washed four times with efflux buffer
(EB) [136 mM NaNO3, 3 mM KNO3, 2 mM Ca(NO3) 2, 0.5 mM MgSO4, 10 mM
glucose, 20 mM HEPES (pH 7.5)] to completely remove extracellular iodide.
Next, cells were left for equilibration during 10 min at 37°C in EB (first set of
replicates) or in EB containing 10 M cell-permeable CFTR-specific inhibitor
172 (Merck4Biosciences) (second set of replicates) before 10 M forskolin and
50 M IBMX (3-isobutyl-1-methylxanthine) (both from Sigma) were added for
5 min to allow protein kinase A-dependent CFTR stimulation. The presence of
10 M CFTR inhibitor 172 (second set of replicate experiments) allowed cor-
recting for endogenous non-CFTR-mediated iodide efflux activities and inhibited
overall iodide efflux production by over 95%. Cells from all replicates were then
quickly washed with fresh EB and the dishes completely drained. Cells were lysed
for 5 min in 1 ml of EB–0.5% Triton X-100 (Sigma), scraped, and centrifuged at
16,000  g for 5 min. Two sample aliquots were removed to quantify CFTR by
Western blot analysis and total protein by the use of Precision Red protein assay
reagent (Cytoskeleton, Denver, CO). The iodide content of the lysates was
then determined using an iodide-selective electrode (Consort) connected to
an MP225 general-purpose meter (Mettler Toledo) measuring the voltage dif-
ferences. Sample voltages generated by the iodide in solution were interpolated
from the standard curve generated by measuring 1, 10, 50, and 100 M standard
solutions and normalized to the amount of protein in the sample. The levels of
iodide produced by efflux from transfected cells were calculated as the differ-
ences between the amounts of iodide remaining in inhibitor-172-treated versus
nontreated replicate experiments; values are expressed in nanomoles. The sta-
tistical significance of the data was analyzed using two-tailed Student’s t tests
(Excel) as well as analysis of variance (ANOVA) with Tukey-Kramer’s test
(VassarStats [http://faculty.vassar.edu/lowry/VassarStats.html]).
RESULTS
WNK4 modulates the cell surface abundance of CFTR in
mammalian cells. WNK4 can regulate various ion channels in
a kinase-dependent or -independent manner, and one previous
report identified a role in the expression of CFTR at the cell
surface of Xenopus oocytes (48). In order to confirm this effect
in mammalian cells, we used baby hamster kidney (BHK-21)
cells engineered to stably express human CFTR protein (BHK-
21-CFTR) (26, 38). Those cells have been used to create a
well-characterized model system in the field and were transfected
with GFP empty vector, the GFP-WNK4 wild type (WNK4-wt),
or a GFP-WNK4 kinase-dead (WNK4-kd) mutant. The con-
sequences for the CFTR protein were subsequently analyzed
by three different techniques. First, cell surface proteins were
labeled by biotinylation and isolated from cell lysates by the
use of streptavidin beads. As shown in Fig. 1A, expression of
both WNK4-wt and WNK4-kd increased the amount of CFTR
detected at the cell surface, indicating that the underlying
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effect is not dependent on catalytic kinase activity. Under the
same experimental conditions, the cell surface levels of endog-
enous transferrin receptor 1 (TfR1) did not change (Fig. 1A).
We confirmed that the biotinylation reaction did not label
cytosolic proteins such as tubulin (data not shown) and that
transfection of GFP empty vector did not alter the steady-state
CFTR surface levels.
Second, confocal immunofluorescence microscopy analysis
confirmed an increase in CFTR staining at the cell surface
in WNK4-wt- or WNK4-kd-transfected cells (Fig. 1B). Third,
CFTR-mediated ion transport activity in transfected cells was
determined by an iodide efflux assay following correction for
endogenous non-CFTR-mediated iodide efflux activities through
normalization against a parallel set of cells treated with CFTR
inhibitor 172. These activity assays revealed a roughly 2-fold
increase in iodide release upon WNK4-wt or WNK4-kd ex-
pression (Fig. 1C).
WNK4 exists in a complex with spleen tyrosine kinase (Syk).
In order to identify the molecular mechanism underlying this
effect of WNK4 on CFTR surface expression, we screened
proteins interacting with WNK4 by the use of an antibody
array. To this end, HEK293 cells were transfected with Myc-
tagged WNK4 and lysed under nondenaturing conditions to
preserve protein-protein interactions, and the extract was in-
cubated with the antibody array. Briefly, the array contained
antibodies against 400 cellular proteins involved in signal trans-
duction that are able to bind their cognate proteins from the
cell lysate. Those proteins forming a complex with Myc-WNK4
in the lysate were revealed by chemiluminescence staining of
the array membrane with an anti-Myc peroxidase conjugate.
After subtraction of unspecific signals generated by the anti-
Myc antibody alone, one clear positive hit for WNK4 was
obtained at the position of anti-spleen tyrosine kinase (Syk)
(Fig. 2A).
For confirmation of the observed interaction, Myc-WNK4
and YFP-Syk were cotransfected into HEK293 cells (as well
FIG. 1. Expression of WNK4 in mammalian cells increases cell
surface expression of CFTR. BHK-21 cells stably expressing human
CFTR protein were transfected with GFP-tagged expression vectors
encoding GFP alone (vector) or WNK4 wild type (wt) or its kinase-
dead mutant WNK4-kd and then analyzed by different techniques for
changes in the cell surface expression of CFTR. (A) Biotinylation of
cell surface proteins. Representative Western blots from a total of 7
independent experiments are shown, demonstrating the presence of
CFTR protein and the transferrin receptor (TfR) either in the fraction
of biotinylated cell surface proteins following pulldown with strepta-
vidin beads (Surface) or in whole-cell lysates (Input). The differences
in CFTR band intensities were quantified and are given below the blot
as severalfold increases over control values  standard deviations. No
changes were observed in the case of the transferrin receptor. Cell
lysates were further stained to document the expression levels of trans-
fected GFP, GFP-WNK4-wt, or GFP-WNK4-kd. (B) Confocal immu-
nofluorescence microscopy. In order to demonstrate qualitatively the
effect on CFTR surface expression, the indicated GFP-tagged vectors
were diluted so that most microscopic fields contained transfected and
nontransfected cells side by side. Cells were fixed and stained with
anti-CFTR antibody 570 followed by anti-mouse Alexa 568 conjugate.
Images were recorded sequentially for DAPI, GFP, and Alexa stain-
ings. GFP-positive cells represent the successfully transfected cells. (C)
CFTR-mediated ion transport by iodide efflux (for details, see Mate-
rials and Methods). The statistical significance of the differences was
determined using both two-tailed Student’s t tests (*, P  0.0001) and
ANOVA (P 0.0001, comparing the three sample groups) followed by
Tukey-Kramer’s test (, P  0.01 compared to the control). All ex-
periments were repeated in at least three independent transfection
assays.
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as GFP alone and Myc-hnRNP A1 as respective controls) and
immunoprecipitated. Anti-GFP antibodies immunoprecipi-
tated Syk, and the presence of WNK4 was clearly detected in
the YFP-Syk precipitate but not with YFP alone. In contrast,
anti-Myc antibodies precipitated WNK4 and the presence of
Syk was detected with anti-YFP antibodies. Also, as a control,
the unrelated nuclear protein Myc-hnRNP A1 was expressed
but did not coimmunoprecipitate with Syk (Fig. 2B). The en-
dogenous WNK4 protein could not be immunoprecipitated
due to a lack of suitable commercial antibodies.
Because HEK293 cells do not express endogenous CFTR
protein, the coimmunoprecipitation studies were repeated with
parental and CFTR-expressing BHK-21 cells. The results con-
firmed that Syk precipitated specifically with Myc-WNK4 but
not with Myc-hnRNP A1 and that this interaction occurred
independently of the presence of the CFTR protein (Fig. 2C).
Syk forms a complex with CFTR and phosphorylates the
NBD1 domain in vitro. Because no functional interaction be-
tween protein kinase Syk and CFTR has been described to
date, we first tested whether the two proteins were able to
coimmunoprecipitate. BHK-21-CFTR cells were transfected
to express either YFP protein or YFP-Syk, and both were
immunoprecipitated from cell lysates by the use of the anti-
GFP antibody. The precipitates revealed the presence of
CFTR protein only in the case of YFP-Syk (Fig. 3A).
We then tested whether the CFTR protein was a Syk sub-
strate in vitro. BHK-21-CFTR cells were lysed under stringent
SDS-containing RIPA buffer conditions to immunoprecipitate
the CFTR protein, which was then preincubated with unlabeled
ATP to saturate potential contaminating phosphorylation ac-
tivities. Independently, YFP-Syk-wt or a kinase-dead mutant
(YFP-Syk-kd) was immunoprecipitated from transfected cells
in RIPA buffer so that contamination with other kinases from
the cell lysate was minimized. The beads were then washed in
protein kinase buffer, added to the CFTR beads, and incubated in
the presence of radioactive ATP and inhibitors of protein serine/
threonine kinases known to phosphorylate CFTR (1). As shown
in Fig. 3B, Syk-wt autophosphorylated and phosphorylated CFTR
whereas Syk-kd showed no such activities.
We analyzed the CFTR peptide sequence and found a single
Syk recognition motif (Y-D/E-D/E-X) at Tyr512 in the first
nucleotide binding domain (NBD1) (Fig. 3C). We thus tested
next whether Syk could phosphorylate the NBD domain at
Tyr512 in vitro. YFP-Syk-wt or YFP-Syk-kd was immunopre-
cipitated as described above, and the beads were washed in
protein kinase buffer and incubated with radioactive ATP in
the presence of isolated NBD1 as a substrate. In a first set of
experiments, recombinant NBD1 (kind gift of P. J. Thomas)
was found to be phosphorylated by Syk-wt but not by Syk-kd
(Fig. 4, left panels). In order to demonstrate that Tyr512 was
indeed the residue targeted by this activity, the NBD1 coding
sequence was point mutated to a phenylalanine at position 512
and then expressed as Sumo-tagged recombinant protein in
order to yield acceptable amounts of soluble mutant NBD1.
While Syk clearly phosphorylated Sumo-NBD1-wt, it no longer
phosphorylated the NBD1-Y512F mutant (Fig. 4, middle pan-
els). Since the phosphorylation of recombinant proteins in vitro
can sometimes result from an incorrect conformation, we
confirmed these data using the Myc-tagged NBD1 domain
expressed in HEK293 cells as a substrate for the Syk kinase
FIG. 2. WNK4 forms a protein complex with Syk protein kinase.
(A) Identification of Syk as a WNK4-interacting protein by the use of
an antibody array. Lysates of HEK293 cells transfected with either
Myc-WNK4-wt or empty vector (Control) were incubated with an
antibody array. WNK4-protein interactions were then revealed by
chemiluminescence using an anti-Myc peroxidase-conjugated anti-
body. The relevant array areas are shown with one WNK4-specific
signal that corresponded to the position of Syk (circle). (B) Coimmu-
noprecipitation experiments to confirm the observed WNK4-Syk in-
teraction. HEK293 cells were cotransfected with Myc-WNK4-wt and
YFP-Syk-wt as well as with YFP alone and Myc-hnRNP A1 as
controls, lysed under nondenaturing conditions, and incubated with
either anti-GFP antibodies to precipitate Syk (top panels) or with
anti-Myc antibodies to precipitate WNK4 (bottom panels). Results
of Western blot analyses of the expression levels in whole-cell
lysates (Input) and the immunoprecipitated fractions (IP) are
shown. As respective controls, the YFP protein and Myc-tagged-
hnRNP A1 were used. Note that immunoprecipitated YFP-Syk
pulls down WNK4 and, in contrast, that immunoprecipitates of
Myc-WNK4 revealed the presence of Syk. (C) Validation of the
observed interaction in CFTR-expressing BHK-21 cells. Parental
and CFTR-expressing BHK-21 cells were cotransfected with YFP-
Syk-wt and either Myc-WNK4-wt or Myc-hnRNP A1 (control).
Myc-tagged proteins were immunoprecipitated and analyzed by
Western blotting as described above. All experiments were repeated
in at least three independent transfection assays.
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assay. Whereas the immunoprecipitated Myc-NBD1 domain
was found to be phosphorylated by Syk in vitro, the corre-
sponding NBD1-Y512F mutant was not recognized as a sub-
strate (Fig. 4, right panels). Although this approach does not
guarantee that Syk recognizes the isolated NBD1 with the
same efficiency as full-length CFTR, the results confirmed
qualitatively that Syk can phosphorylate only the wt but not
NBD1-Y512F.
WNK4 inhibits NBD1 phosphorylation by Syk. Since, as de-
scribed above, we found that Syk interacts with WNK4, we
tested the effect of WNK4 on NBD1 phosphorylation by Syk.
FIG. 3. CFTR is a substrate for Syk protein kinase and contains a
Syk substrate motif in the NBD1 domain. (A) CFTR coimmunopre-
cipitates with Syk. YFP vector or YFP-Syk-wt was transfected into
CFTR-expressing BHK-21 cells and immunoprecipitated with anti-
GFP antibodies. Whole-cell lysates and precipitates were then sepa-
rated in acrylamide gels optimized for the best resolution of CFTR
bands B and C. Western blots revealing the expression levels of YFP,
YFP-Syk (anti-GFP), and CFTR (rabbit anti-CFTR Lis1) in whole-cell
lysates (Input) and in the immunoprecipitated fractions (IP) are
shown. Note that only YFP-Syk coprecipitated the CFTR protein. The
second visible Syk protein band occurred as an effect of the CFTR-
specific gel conditions. (B) CFTR is a substrate for protein kinase Syk.
Full-length CFTR protein was immunoprecipitated with antibody
clone 570 from BHK-21-CFTR cells and then mixed with radioactive
ATP and beads containing either Syk-wt or Syk-kd mutant. To reduce
nonspecific background phosphorylation, the immunoprecipitated
CFTR protein was premixed with unlabeled ATP and then assayed in
the presence of protein serine/threonine kinase inhibitors. Samples
were separated by gel electrophoresis and transferred to PVDF blot-
ting membranes, and the membranes were exposed to X-ray films
(Kinase Assay) detecting incorporated radioactive [32P]phosphate, fol-
lowed by Western blot analysis to document the levels of immunopre-
cipitated proteins (Input). Note that only Syk-wt was able to phosphor-
ylate CFTR as well as to autophosphorylate. (C) Model of the CFTR
ion channel structure with 12 transmembrane domains, two nucle-
otide-binding domains (NBD), and a regulatory domain (R). Below
the model, the sequence of the cytoplasmic nucleotide binding-domain
1 (NBD1) is highlighted in black; the relevant residues containing the
Syk substrate motif are underlined and shown in greater detail below
the sequence. Note that tyrosine 512 is close to phenylalanine 508, the
residue most frequently mutated in cystic fibrosis patients.
FIG. 4. Syk phosphorylates the CFTR NBD1 domain in vitro. YFP
vector or YFP-Syk-wt or YFP-Syk-kd was transfected into HEK293
cells, immunoprecipitated, and tested in in vitro protein kinase assays
for the ability to phosphorylate CFTR. The added substrates were
recombinant NBD1 domain (left panels), Sumo-tagged recombinant
NBD1 or its Y512F derivative (middle panels), or transfected Myc-
tagged NBD1 or Myc-NBD1-Y512F (right panels) immunoprecipi-
tated from HEK293 cells. Samples were separated by gel electropho-
resis and transferred to PVDF blotting membranes. Images from X-ray
films (Kinase Assay) detecting radiolabeled proteins are shown; black
arrowheads indicate the positions of NBD1 detected with anti-CFTR
clone L12B4 on a subsequent Western blot. Note that Syk-wt (but not
the Syk-kd mutant) phosphorylates NBD1 (besides Syk autophosphor-
ylation) and that phosphorylation by Syk is abolished after mutating
Y512 to phenylalanine (F). Phosphorylation of Myc-tagged NBD1 was
2.6-fold higher in the presence of Syk-wt than in the presence of vector
alone or NBD1-Y512F background levels. In order to document equal
quantities of immunoprecipitated Syk or NBD1 substrate protein,
membranes were subsequently subjected to immunostaining with anti-
GFP and anti-CFTR antibody L12B40 (Input). The white arrowhead
indicates the position of immunoglobulin light chains which retained
some radioactive phosphate. Experiments were repeated in at least
three independent assays.
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For this purpose, Myc-WNK4-wt or WNK4-kd was expressed,
immunoprecipitated, and added to Syk-wt and recombinant
NBD1 in the in vitro kinase assay. It was found that the pres-
ence of either WNK4-wt or WNK4-kd completely prevented
Syk from phosphorylating NBD1 (Fig. 5A). In order to further
study how WNK4 inhibits the NBD1 phosphorylation by Syk,
we analyzed whether WNK4 could directly phosphorylate Syk
in vitro. Myc-WNK4-wt was expressed in cells, immunoprecipi-
tated, and mixed in in vitro kinase assays with either Syk-wt or
Syk-kd. As a positive control, recombinant OSR1 was added as
a known WNK substrate (44) and found to become phosphor-
ylated by WNK4 (Fig. 5B). In contrast, Syk-kd was not phos-
phorylated by WNK4, and Syk-wt revealed only its own auto-
phosphorylation level without any evidence for additional
phosphorylation by WNK4.
Syk activity modulates the expression of CFTR at the cell
surface. Since Syk phosphorylated the NBD1 domain of CFTR
in vitro, we asked whether Syk can modulate the expression of
CFTR at the cell surface. Thus, BHK-21-CFTR cells were
transfected with YFP-tagged expression vectors encoding YFP
alone (vector), Syk-wt, or Syk-kd and then analyzed for expres-
sion of CFTR at the cell surface by biotinylation of cell surface
proteins, immunofluorescence microscopy, and iodide efflux
assays, all in comparison to the described effect of wt WNK4.
Expression of Syk-wt led to a decrease in the amount of CFTR
at the cell surface both as biotinylated protein (Fig. 6A) and as
revealed by immunofluorescence staining (Fig. 6B). In con-
trast, expression of Syk-kd increased the amounts of plasma
membrane-associated CFTR in both assays to levels compara-
ble to those obtained upon expression of WNK4-wt. These
data were confirmed by iodide efflux measurements (Fig. 6C)
demonstrating that the observed changes in surface amounts of
CFTR reflected different capacities of the cells to produce
iodide efflux upon forskolin-IBMX stimulation.
Endogenous Syk and WNK4 regulate CFTR surface expres-
sion in human airway epithelial cells. In order to test the
physiologic relevance of our findings, we validated the effect
of Syk and WNK4 in the CF-bronchial epithelial cell line
CFBE41o- (wt-CFBE) (3). These cells were found to express
endogenous Syk and WNK4, and their respective expression
levels were successfully reduced upon transfection with specific
siRNAs within 48 h (Fig. 7A). Transfected wt-CFBE cells were
thus analyzed by biotinylation of cell surface proteins to deter-
mine the expression levels of CFTR at the cell surface under
these conditions. As shown in Fig. 7B, the downregulation of
Syk promoted CFTR surface levels, thus confirming the inhib-
itory role in this process that we identified above. In contrast,
the depletion of endogenous WNK4, which we found to an-
tagonize Syk as described above, led to a clear decrease in
CFTR levels at the cell surface. Under the same experimental
conditions, the cell surface levels of the endogenous transferrin
receptor (TfR) did not change (Fig. 7B).
Mutation of tyrosine 512 is sufficient to promote changes in
the expression of CFTR at the cell surface. In order to dem-
onstrate that the observed phosphorylation in the NBD1 do-
main is functionally relevant in vivo, Tyr512 was changed by
site-directed mutagenesis into either nonphosphorylatable Phe
or a phosphomimetic Glu residue. These CFTR mutants were
stably transfected into parental BHK-21 cells, and CFTR ac-
tivity was measured by the iodide efflux technique (Fig. 8A).
FIG. 5. WNK4 inhibits Syk-mediated NBD1 phosphorylation. (A)
WNK4 inhibits NBD1 phosphorylation by Syk. YFP-Syk-wt, YFP-Syk-
kd, GFP-WNK4-wt, or GFP-WNK4-kd was transfected into HEK293
cells, immunoprecipitated, and pooled as indicated to test for the
ability to phosphorylate recombinant NBD1 in in vitro protein kinase
assays. Samples were separated and analyzed as described in the leg-
end to Fig. 3B. Note that Syk and WNK4 autophosphorylate and that
the presence of WNK4 prevents Syk from phosphorylating NBD1.
(B) WNK4 does not phosphorylate Syk in vitro. YFP-Syk-wt, YFP-Syk-
kd, or Myc-WNK4-wt was transfected into HEK293 cells, immunopre-
cipitated, and pooled as indicated for in vitro protein kinase assays. As
a positive control, Myc-WNK4-wt was incubated with recombinant
OSR1, a previously described substrate. Samples were separated and
analyzed as described in the legend to Fig. 4. Note that WNK4 phos-
phorylates OSR1 but not the Syk proteins. Experiments were repeated
in at least three independent assays.
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CFTR-Y512E-expressing cells showed a significant decrease in
CFTR-mediated ion transport, whereas cells expressing CFTR
Y512F released almost twice the amount of iodide as wt
CFTR-expressing cells. These data were found to correlate to
the increased amount of biotinylated CFTR protein at the cell
surface compared to that seen with BHK-21-CFTR cells (Fig.
8B). These mutants thus mimic the effects on CFTR of trans-
fecting either Syk-wt or Syk-kd. To further confirm that Tyr512
mediates the observed effects of Syk and WNK4 in vivo, we
first cotransfected the cells with nonphosphorylatable
CFTR-Y512F and YFP-Syk-wt. Surface biotinylation revealed
that Syk-wt could no longer reduce CFTR-Y512F surface ex-
pression levels (Fig. 8B, middle two lanes). Second, cells were
cotransfected with the phosphomimetic CFTR-Y512E mutant
and Myc-WNK4-wt. Under these conditions, expression of
WNK4 was unable to raise surface levels of the CFTR-Y512E
mutant protein (Fig. 8B, right two lanes) to those seen with wt
CFTR (second lane from left).
DISCUSSION
The data presented in this work provide two novel insights
into the regulation of cell surface expression of CFTR. First,
we show that the CFTR protein is a substrate for phosphory-
lation by protein kinase Syk at NBD1 residue Tyr512, leading
to a reduction in the cell surface expression of CFTR. Second,
we describe an antagonistic role for WNK4 and Syk in regu-
lating the cell surface expression of CFTR.
In our experiments, Syk was initially identified as a WNK4
partner protein in HEK293 cells when proteins involved in
signal transduction were screened for formation of complexes
with Myc-WNK4 under nondenaturing conditions. The inter-
action was clearly confirmed by coimmunoprecipitation when
either WNK4 or Syk was pulled down (Fig. 2). The observed
interaction occurred in both human HEK293 and rodent
BHK-21 cells and was independent of the presence of CFTR.
Because expression of WNK4 enhanced the amount of CFTR
at the plasma membrane (Fig. 1), we searched for a possible
role of Syk in this process and found a Syk phosphorylation
motif at Tyr512 of the CFTR sequence, i.e., in its first nucle-
otide binding domain (NBD1). In protein kinase assays per-
formed in vitro, this CFTR domain was indeed found to be
phosphorylated by Syk at Tyr512. Furthermore, when Syk is
overexpressed in cells, it associates with and coimmunoprecipi-
tates CFTR, an interaction resulting in a slight reduction in the
amount of cell surface biotinylated CFTR. Even more signifi-
cant was the outcome of expression of a kinase-dead (domi-
nant-negative) Syk mutant, which may interact with CFTR but
not phosphorylate it; expression of the mutant caused a signif-
icant increase in the level of cell surface CFTR. This indicates
that Syk activity normally restricts expression of CFTR at the
plasma membrane. This increase in surface CFTR was con-
firmed by fluorescence microscopy and by measuring CFTR-
FIG. 6. WNK4 and Syk have antagonistic effects on the cell surface
expression of CFTR. BHK-21-CFTR cells were transiently transfected
with GFP-tagged expression vectors encoding YFP alone (vector),
WNK4-wt, Syk-wt, or Syk-kd and then analyzed by different techniques
for changes in expression levels of CFTR at the cell surface (for more
details, see the legend to Fig. 1). (A) Biotinylation of cell surface
proteins. (B) Confocal immunofluorescence microscopy. YFP-positive
cells represent the successfully transfected cells. (C) CFTR-mediated
ion transport by iodide efflux. Note that expression of Syk-wt decreased
whereas that of Syk-kd or WNK4-wt increased surface CFTR levels
compared to control cell results. Experiments were repeated in at least
three independent transfection assays. The statistical significance of
the differences was determined using both two-tailed Student’s t tests
(*, P  0.006; **, P  0.0001) and ANOVA (P  0.0001, comparing
the four sample groups) followed by Tukey-Kramer’s test (, P  0.01
compared to control results).
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mediated iodide efflux levels in living cells (Fig. 6). Finally,
CFTR mutations mimicking either a constitutive phosphory-
lated or a nonphosphorylated Tyr512 were sufficient to pro-
voke the corresponding changes in the CFTR cell surface
abundance and iodide efflux levels (Fig. 8).
Together, these data make a convincing case that phosphor-
ylation of CFTR at Tyr512 by Syk is a novel regulatory mech-
anism to modulate the amount of CFTR present at the plasma
membrane. Although serine/threonine phosphorylation of CFTR
was known to occur in the regulatory domain of CFTR, leading
to channel opening and activation of transport activity (11),
our data on Syk reveal a previously unknown role for tyrosine
phosphorylation in the NBD1 domain and a role in the regu-
lation of CFTR expression at the cell surface. Our data further
reveal that WNK4 acts in a manner antagonistic to Syk and
promotes surface expression of CFTR.
The physiological relevance of these findings is strongly sup-
ported by the fact that endogenous expression of Syk and
WNK4 was detected in airway epithelial cells and that their
experimental downregulation clearly affected CFTR cell sur-
FIG. 7. Endogenous WNK4 and Syk affect the cell surface expres-
sion of CFTR in bronchial epithelial cells. Human wt-CFBE cells were
transiently transfected with small interfering RNA (siRNA) oligonu-
cleotides to downregulate the endogenous expression of either Syk or
WNK4. (A) Expression levels of Syk and WNK4 determined by RT-
PCR and agarose gel electrophoresis as well as downregulation of the
corresponding transcripts after 48 h are shown. Two serial 2-fold di-
lutions of the control sample were also loaded to allow estimation of
the degree of depletion (top panels). Western blot confirmation of
protein downregulation was possible only for endogenous Syk due to
the lack of suitable anti-human WNK4 antibodies. However, the effi-
ciency of si-RNA-mediated depletion of WNK4 protein was clearly
demonstrated using transfected Myc-WNK4 (bottom panels). (B) Bio-
tinylation of cell surface proteins. The effect of Syk or WNK4 depletion
on changes in cell surface expression of CFTR and TfR was deter-
mined by Western blot analysis, as described in the legend to Fig. 1.
Note that surface CFTR levels increased upon downregulation of Syk
expression, whereas in the case of WNK4, the amount of channel at
the cell surface decreased compared to control cell results. Under
these conditions, TfR surface levels were not affected.
FIG. 8. The presence of phosphomimetic mutants of CFTR ty-
rosine 512 is sufficient to change CFTR cell surface expression.
BHK-21 cells were stably transfected with CFTR mutant constructs
carrying point mutations in tyrosine 512 so that either a phosphomi-
metic glutamic acid residue (Y512E) or an unphosphorylatable phe-
nylalanine residue (Y512F) was present. Cells were analyzed by dif-
ferent techniques for determination of changes in levels of expression
of CFTR at the cell surface, as described in the legend to Fig. 1.
(A) CFTR-mediated ion transport by iodide efflux. The statistical
significance of the differences was determined using both two-tailed
Student’s t tests (*, P 0.03; **, P 0.005) and ANOVA (P 0.0001,
comparing the three sample groups) followed by Tukey-Kramer’s test
(, P  0.05; ‡, P  0.01 [for comparisons to wt results]). (B) Bio-
tinylation of cell surface proteins. Note that CFTR-Y512E is less
abundant but that CFTR-Y512F is more abundant at the cell surface
than wt CFTR. In addition, it was no longer possible to decrease the
surface abundance of CFTR-Y512F by transfection of YFP-Syk-wt,
and the abundance of CFTR-Y512E was no longer increased by ex-
pression of GFP-WNK4-wt.
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face expression (Fig. 7). These experiments confirmed that Syk
has an inhibitory role with respect to CFTR surface levels and
that WNK4 positively regulates these. Expression of Syk in
primary or transformed human bronchial epithelial cells was
also previously confirmed by others (42). A previous analysis of
WNK4 in extrarenal tissues found expression in lung and other
chloride-transporting epithelia, including sweat ducts, colonic
crypts, pancreatic ducts, and epididymis (19). Thus, the tissue-
specific WNK4 expression pattern largely overlaps with that of
CFTR. Given that WNK kinases can be activated by changes in
extracellular osmolarity (21), it is tempting to postulate that
WNK4 responds to fluctuations of the airway surface fluid and
adjusts the amount of CFTR activity accordingly.
The in vitro phosphorylation of CFTR NBD1 at Tyr512 by
Syk was inhibited by WNK4-wt as well as by its WNK4-kd
mutant. Thus, the inhibition was most likely mediated by the
protein-protein interaction that we observed between Syk and
WNK4, the molecular details of which remain to be deter-
mined. Other WNK4-mediated effects on ion channels were
also previously described as independent of the presence of
kinase and include the inhibition of ROMK (22) and of ENaC
(34) surface expression in Xenopus oocytes. In both cases,
changes in the endocytosis of the respective channels are in-
volved, albeit through different molecular pathways: while the
inhibitory effect of WNK4 on ROMK involves binding to the
linker protein intersectin to facilitate clathrin-dependent en-
docytosis (15), the downregulation of ENaC is most likely
mediated by the E3 ubiquitin ligase Nedd4-2 to direct ENaC
into the lysosomal pathway for degradation (34). Whether the
antagonistic effects of WNK4 and Syk on CFTR also involve
endocytosis or instead involve changes in membrane traffic and
CFTR delivery remains to be determined; however, the effect
of WNK4 on CFTR surface levels is clearly specific, because no
changes in endogenous transferrin receptor surface levels were
observed under the same experimental conditions (Fig. 1A and
7B). Intriguingly, when we expressed the Syk-kd mutant, lead-
ing to an increase in surface CFTR levels, our immunofluo-
rescence analysis revealed that this mutant colocalized at the
plasma membrane with sites of increased CFTR staining
(Fig. 6B). This suggests that, under normal conditions, Syk
is recruited to the plasma membrane by CFTR and then
phosphorylates it, triggering CFTR endocytosis. The pres-
ence of WNK4 would then sequester Syk and increase re-
tention of CFTR at the cell surface. The upstream signals
regulating activation or expression of Syk and WNK4 re-
main to be determined.
Our findings have several remarkable implications. First, the
WNK4/Syk interplay identified for CFTR may also operate in
the regulation of other chloride cotransporters. Given that an
increase in apical CFTR activity would require concomitant
activation of basolateral ion channels to coordinate transepi-
thelial chloride flux (20), it is tempting to speculate that WNK4
and/or Syk controls this coordination. Second, the WNK4/Syk
pathway may be of therapeutic interest for patients with cystic
fibrosis. The most frequent mutation in patients is deletion of
phenylalanine 508, which causes increased proteolytic degra-
dation of the misfolded mutant CFTR protein. Interestingly,
however, the mutant protein exhibits some residual chloride
channel activity and could partially reduce disease severity if its
retention at the plasma membrane were improved (2). Because
our data suggest that Syk normally inhibits CFTR surface ex-
pression, a relevant topic in future studies might be the inhi-
bition of Syk to favor the prevalence at the plasma membrane
of mutant CFTR proteins retaining some chloride channel
activity (e.g., F508del-CFTR). Third, Syk inhibitors may be
beneficial in cystic fibrosis therapy, because the disease is char-
acterized by chronic lung inflammation due to impaired clear-
ance of the thick mucus that forms in the absence of CFTR-
mediated chloride transport (4). Syk inhibitors are currently
used in the clinic to inhibit inflammation and treat allergic
rhinitis and rheumatoid arthritis (36, 40). The efficacy of such
treatment in due to the role of Syk in immunoreceptor signal-
ing in leukocytes (27, 36), but recent studies have suggested
that Syk also functions in tumor necrosis factor-induced nitric
oxide production by airway epithelial cells (41).
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